Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health (NASDAQ:JAGX) announced on October 24, 2025 that, effective October 20, 2025, it granted inducement restricted stock units (RSUs) under Nasdaq Listing Rule 5635(c)(4).
The company awarded 600 RSUs to New Employee 1, 600 RSUs to New Employee 2, and 300 RSUs to New Employee 3, for a total of 1,500 RSUs. Each grant vests over one year from the employee's hire date and is conditioned on continued service through the applicable vesting dates. The grants were approved by Jaguar's Compensation Committee as material inducements to employment.
Jaguar Health (NASDAQ:JAGX) ha annunciato il 24 ottobre 2025 che, a partire dal 20 ottobre 2025, ha concesso unità di azioni restritte da incentivo (RSU) ai sensi della Nasdaq Listing Rule 5635(c)(4).
L'azienda ha assegnato 600 RSU al Nuovo Dipendente 1, 600 RSU al Nuovo Dipendente 2 e 300 RSU al Nuovo Dipendente 3, per un totale di 1.500 RSU. Ogni assegnazione matura nell'arco di un anno dalla data di assunzione del dipendente e è soggetta alla continuazione del servizio fino alle rispettive date di vesting. Le assegnazioni sono state approvate dal Compensation Committee di Jaguar come incentivi sostanziali all'assunzione.
Jaguar Health (NASDAQ:JAGX) anunció el 24 de octubre de 2025 que, con efecto a partir del 20 de octubre de 2025, concedió unidades de acciones restringidas por incentivo (RSU) conforme a la Regla 5635(c)(4) de Nasdaq Listing.
La compañía otorgó 600 RSU al Nuevo Empleado 1, 600 RSU al Nuevo Empleado 2 y 300 RSU al Nuevo Empleado 3, para un total de 1,500 RSU. Cada asignación se consolida en el transcurso de un año desde la fecha de contratación del empleado y está condicionada a la continuidad del servicio hasta las fechas de vesting aplicables. Las asignaciones fueron aprobadas por el Comité de Compensación de Jaguar como incentivos materiales para el empleo.
Jaguar Health (NASDAQ:JAGX)는 2025년 10월 24일 발표했다. 2025년 10월 20일부터 발효되어 Nasdaq Listing Rule 5635(c)(4)에 따라 유인( inducement) 제한 주식 단위(RSU)를 부여했다고.
회사는 신규 직원 1에게 600 RSU, 신규 직원 2에게 600 RSU, 신규 직원 3에게 300 RSU를 부여하여 총 1,500 RSU가 되었다. 각 부여는 직원의 입사일로부터 1년 동안 귀속되며 해당 귀속 날짜까지의 지속적 근무를 조건으로 한다. 이 부여는 Jaguar의 보상위원회가 고용에 대한 실질적 유인으로 승인했다.
Jaguar Health (NASDAQ:JAGX) a annoncé le 24 octobre 2025 que, à compter du 20 octobre 2025, elle a accordé des unités d’actions restreintes de participation (RSU) conformément à la règle 5635(c)(4) de Nasdaq Listing.
La société a attribué 600 RSU au Nouvel Employé 1, 600 RSU au Nouvel Employé 2 et 300 RSU au Nouvel Employé 3, pour un total de 1 500 RSU. Chaque attribution se vête sur une période d’un an à partir de la date d’embauche de l’employé et est conditionnée à la poursuite du service jusqu’aux dates de vesting applicables. Les attributions ont été approuvées par le Comité de Rémunération de Jaguar comme incitations matérielles à l’emploi.
Jaguar Health (NASDAQ:JAGX) gab am 24. Oktober 2025 bekannt, dass mit Wirkung zum 20. Oktober 2025 sie Inducement-Beschränkte Aktieneinheiten (RSUs) gemäß Nasdaq Listing Rule 5635(c)(4) gewährt hat.
Das Unternehmen gewährte 600 RSUs an Neuen Mitarbeiter 1, 600 RSUs an Neuen Mitarbeiter 2 und 300 RSUs an Neuen Mitarbeiter 3, insgesamt 1.500 RSUs. Jede Zuteilung vestet sich über ein Jahr ab dem Einstellungsdatum des Mitarbeiters und ist an die fortlaufende Zustimmung bis zu den entsprechenden Vesting-Terminen gebunden. Die Zuteilungen wurden vom Compensation Committee von Jaguar als wesentliche Anreize zur Anstellung genehmigt.
Jaguar Health (NASDAQ:JAGX) أعلنت في 24 أكتوبر 2025 أن اعتباراً من 20 أكتوبر 2025 منحت وحدات أسهم مقيدة كحافز (RSUs) بموجب القاعدة 5635(c)(4) في Nasdaq Listing.
منحت الشركة 600 RSU للموظف الجديد 1، و600 RSU للموظف الجديد 2، و300 RSU للموظف الجديد 3، ليصل الإجمالي إلى 1,500 RSU. كل منحة تستحق خلال سنة واحدة من تاريخ تعيين الموظف وهي مشروطة باستمرار الخدمة حتى تواريخ الاستحقاق المعنية. وقد تمت موافقة المنح من قبل لجنة التعويض في Jaguar كحوافز جوهرية للتوظيف.
- None.
- None.
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / October 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 20, 2025, the Company granted 600 restricted stock units (RSUs) to New Employee 1, 600 RSUs to New Employee 2, and 300 RSUs to New Employee 3.
The RSUs for New Employees 1, 2 and 3 vest over one year starting from each employee's date of hire. The RSUs for New Employees 1, 2 and 3 were granted as an inducement material to each employee's acceptance of employment by the Company and were approved by the Compensation Committee of Jaguar's Board. Vesting of the RSUs is subject to each new employee's continued service with Jaguar through the applicable vesting dates.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Canalevia-CA1, visit canalevia.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Jaguar Health (JAGX) announce on October 24, 2025 about employee RSU grants?
How do the Jaguar Health (JAGX) RSUs vest for the new employees?
Why were the RSUs granted under Nasdaq Rule 5635(c)(4) for JAGX on October 20, 2025?
How many total RSUs did Jaguar Health (JAGX) grant to new hires on October 20, 2025?
Will the Jaguar Health (JAGX) inducement RSUs immediately increase outstanding shares?
Who approved the JAGX inducement RSU grants announced October 24, 2025?
